Tuijin Jishu/Journal of Propulsion Technology
ISSN: 1001-4055
Vol. 45 No. 4 (2024)

Investigating the Pharmacokinetics of Botulinum Toxin Type A in Chronic Migraine Management

Zuhair Muhammed Alben Ahmed [1], Abbad Ali Alnasser [2], Amnah Mustafa Alshakhs [3], Huda Saleh Aloais [4], Hassan Amer Asiri [5], Albatoul Ahmed Alhefzi [6], Khadijah Ahmad Alzaqaan [7], Layla Habib Alhedaibi [8], Zainab Ahmed Alshakhs [9], Nora Salih Alharbi [10], Batool Yaqub Althuwaini [11], Maryam Habeb Almuabed [12], Bdour Hussain Alawad [13], Hamedh Hussain Bo athab [14], Sahar Hussain Alawad [15], Saja Abdalgani Aleid [16], Mariam Ali Albusror [17], Abdullah Ibrahim Alwabari [18], Laila Hassan Alhamad [19], Jafar Saleh Alnajjad [20]

[1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20] *Ministry of Health, Saudi Arabia*

Abstract:- Frequent and intense headaches are the hallmark of chronic migraine (CM), a crippling neurological condition that severely lowers quality of life. Clinical studies have shown that botulinum toxin type A (BTX-A) can lessen the frequency and severity of migraines, making it an effective therapy for CM. Nevertheless, nothing is known about the pharmacokinetics of BTX-A in the treatment of persistent migraines. The absorption, distribution, metabolism, and excretion (ADME) of BTX-A in the treatment of persistent migraines is examined in this study. By means of imaging methods, blood serum tests, and clinical observations, we investigate the temporal dynamics of BTX-A in the human body after injection. The study also assesses patient-specific variables, injection location, and dosage variation as they affect the pharmacokinetics of BTX-A. According to the results, BTX-A primarily acts at the injection site and has little systemic absorption. Additionally, the results imply that BTX-A's therapeutic benefits last for a number of months, supporting its usage in CM therapies on a periodic basis. By shedding light on the pharmacokinetic characteristics of BTX-A, this study helps to enhance patient outcomes and treatment regimens for persistent migraines.

Keywords*: Chronic migraine, Botulinum toxin type A, Pharmacokinetics, Absorption, distribution, metabolism, and excretion (ADME), Migraine management, Therapeutic effects.*

1. Introduction

Chronic migraine (CM), a complex and debilitating neurological disorder, affects a significant portion of the global population. The International Classification of Headache Disorders (ICHD-3) defines CM as headaches that last for at least four hours apiece and happen at least fifteen days a month for at least three months. The condition is often associated with other symptoms, such as nausea, vomiting, and sensitivity to light and sound. CM is a major cause of disability worldwide, contributing considerably to healthcare expenses, lowering productivity, and lowering quality of life. According to recent epidemiological research, between two and three percent of individuals suffer from chronic migraines, with women experiencing them more frequently [1,2]. It has been difficult to treat CM, and the pharmacological treatments that are now available have not provided many patients with enough comfort. Traditional therapies for migraines include prophylactic drugs including triptans and antidepressants, beta-blockers, and anticonvulsants. However, these medications frequently have significant adverse effects, are inefficient, or are poorly tolerated by patients, particularly when taken for an extended length of time [3]. Since CM patients frequently experience refractory symptoms, the effectiveness of these therapies is

expected to wane with time. Botulinum toxin type A (BTX-A) is one of the alternative drugs being researched in response to the demand for new and improved therapeutic alternatives.

Botulinum Toxin Type A in Chronic Migraine Treatment:

The bacterium Clostridium botulinum produces the neurotoxic protein known as botulinum toxin type A (BTX-A), which has drawn a lot of interest as a potential therapy for chronic migraine. BTX-A's therapeutic action depends on its capacity to prevent acetylcholine from being released at neuromuscular junctions, which results in momentary muscle paralysis. This characteristic has been effectively used for cosmetic operations (such wrinkle reduction) and, more recently, for the treatment of a number of illnesses, including CM. Based on strong clinical data supporting its effectiveness, the U.S. Food and Drug Administration (FDA) authorized BTX-A in 2010 for the prevention of adult chronic migraines [4].

Although the precise process by which BTX-A reduces migraine is unclear, it is thought to include a number of neuronal mechanisms. It is believed that BTX-A affects CM via acting on sensory nerve terminals, which lowers the release of pain-mediating neurotransmitters in the trigeminal system, including substance P and calcitonin gene-related peptide (CGRP). The therapeutic advantages of BTX-A in lowering the frequency and intensity of migraines may be explained by this reduction of neurogenic inflammation in the peripheral nervous system as well as possible effects on central sensitization [5].

Clinical studies suggest that BTX-A treatment may assist individuals with CM have less severe pain, fewer headache days, and a decreased need for acute medications. In the pivotal Phase 3 PREEMPT trials (2010), which formed the basis for FDA clearance, patients who received BTX-A injections reported a decrease in headache days of about 7.5 days per month as compared to the placebo group. Furthermore, some patients reported at least a 50% monthly reduction in headache incidence [4]. These findings suggest that BTX-A is a good alternative to CM therapy, especially for patients who have not responded to earlier preventative interventions.

The pharmacokinetics (PK) of BTX-A in the treatment of persistent migraines is little known, despite the toxin's efficacy in clinical practice. The study of a drug's absorption, distribution, metabolism, and excretion by the body is known as pharmacokinetics. Important concerns still surround BTX-A, including how the toxin is dispersed throughout the body, how it is digested, how long it stays effective at the site of action, and how it enters the bloodstream after injection. These specifics are essential for maximizing treatment plans, figuring out the right dosage, comprehending adverse effects, and enhancing patient outcomes.

Pharmacokinetics of Botulinum Toxin Type A:

BTX-A has a different pharmacokinetic profile than typical small molecule medications. BTX-A's localized action, which mainly affects the muscles or nerves at the injection site with little systemic absorption, is one of its distinctive features. The majority of the therapeutic impact is really exerted in the local location of the injection, with just a little portion of the toxin entering the circulation after injection. In order to modify the trigeminal nerve activity, which is believed to have a role in the pathophysiology of CM, the toxin is often injected into certain regions surrounding the head and neck. Therefore, elements including the injection location, dosage, and patient characteristics have a big impact on BTX-A's pharmacokinetic profile.

Understanding BTX-A's absorption, distribution, metabolism, and excretion (ADME) has been the main goal of research into its pharmacokinetics for the treatment of CM. According to studies, BTX-A enters the circulation gradually after injection, reaching peak serum concentrations in less than a day. BTX-A's actions are primarily limited to the targeted tissues, and because of its large molecular size, it is often not widely dispersed throughout the body [6]. Though its exact metabolic routes are yet unknown, it is believed that BTX-A is digested in the local tissues and then progressively removed through the urine, where remnants can be seen up to 12 weeks after injection [5].

Current Gaps in Pharmacokinetic Knowledge:

Although BTX-A's efficacy in CM is supported by clinical evidence, nothing is known about its precise pharmacokinetics. For instance, research has not thoroughly examined how individual differences in PK and the

effects of age, body mass index (BMI), and concomitant diseases on the pharmacokinetic profile and clinical results of BTX-A. Furthermore, the fact that BTX-A's effects endure for a long time—many months for the majority of patients—raises concerns regarding the mechanisms behind its protracted activity. Optimizing treatment plans requires an understanding of these factors, which include the frequency of injections, the required dosage of toxin, and the possibility of dose-related adverse effects.

Furthermore, as new formulations and delivery methods (e.g., microspheres or sustained-release systems) are being developed, understanding the pharmacokinetics of these alternative treatments will be essential for evaluating their potential advantages over the standard botulinum toxin injections [7].

2. Materials and Procedures

This section provides a detailed description of the techniques and protocols used to investigate the pharmacokinetics of Botulinum Toxin Type A (BTX-A) in the treatment of chronic migraine. The absorption, distribution, metabolism, and excretion (ADME) of BTX-A in a group of individuals with chronic migraine was examined by clinical and laboratory assessments.

Study Design:

Based on the International Classification of Headache Disorders (ICHD-3) criteria, 100 patients with a diagnosis of chronic migraine participated in this 12-month prospective observational clinical investigation [8]. The purpose of the research was to assess BTX-A's pharmacokinetics while it was being used to treat persistent migraines.

- Time Frame for Study: 12 months
- Patient Population: 100 patients between the ages of 18 and 65 who had been suffering from chronic migraine for a year or more, had not responded to at least two preventive therapies, and satisfied the ICHD-3 criteria for chronic migraine.
- Setting: A tertiary care headache center with specialized capabilities for clinical and pharmacological evaluations served as the study's site.

Criteria for Inclusion and Exclusion:

Criteria for Inclusion:

- Age: 18 to 65 years old
- Diagnosis: Chronic migraine (at least 15 days per month for at least three months, with a daily headache length of at least four hours)
- Insufficient reaction to a minimum of two previous oral or injectable migraine preventive drugs.
- Written informed consent to take part in the research

Criteria for Exclusion:

- History of sensitivities or negative responses to botulinum toxins
- Pregnancy or lactation
- Botulinum toxin injection contraindications (e.g., injection site infection, history of muscle issues) Neurological illnesses other than chronic migraine (e.g., epilepsy, Parkinson's disease)
- Systemic botulinum toxin use within 6 months before study entrance. These standards were created to guarantee patient population homogeneity and remove any confounding variables that can affect BTX-A's pharmacokinetics.

Intervention: Injection of Botulinum Toxin Type A:

- A uniform dosage of 155 units of BTX-A (Botox®, Allergan, Irvine, CA, USA), the FDA-approved dosage for treating persistent migraines, was administered to the participants. According to [5], the toxin was subcutaneously administered to 31 pre-selected locations around the head and neck region in order to cure persistent migraines. According to current clinical standards, each patient received BTX-A injections in these locations in a standard pattern [5].
- Injection Sites: The attending physician offered accurate anatomical guidance for the frontal, temporal, occipital, and cervical muscles. The forehead, temples, neck, and shoulders—areas commonly impacted by severe migraines—were equally covered by the injections [9].

Pharmacokinetic Assessment:

After BTX-A was administered, a pharmacokinetic assessment was conducted at various intervals. Serum samples, imaging methods, and clinical observations were used to evaluate the ADME parameters (absorption, distribution, metabolism, and excretion).

1. Absorption: Patients' blood was drawn five times after the injection: baseline (pre-injection), one hour, twenty-four hours, one week, three weeks, and six weeks. The enzyme-linked immunosorbent assay (ELISA), a proven method for identifying botulinum toxin in serum, was used to assess the serum concentration of the toxin [10]. The ELISA kits utilized had detection limits in the low picogram range and were specific for botulinum toxin type A. Accurate measurements of systemic absorption after injection were therefore made possible.
2. Distribution: Non-invasive imaging methods, such as MRI and PET scans, were used to evaluate the distribution of BTX-A. At baseline, one week, and twelve weeks after therapy, MRI scans were conducted. To examine the location and distribution of BTX-A at the injection site, PET imaging using a radiolabeled botulinum toxin was also carried out [11]. The localized effects of the toxin as well as any systemic dissemination might be observed thanks to these imaging modalities.
3. Metabolism: By monitoring the time-course of blood toxin levels throughout the research period, the metabolic profile of BTX-A was evaluated. The concentration-time curve derived from the ELISA data was used to calculate the serum half-life of BTX-A. According to earlier research, BTX-A has a lengthy half-life in local tissues, with effects that can persist anywhere from three to four months [12]. In order to determine how long the therapeutic benefits of BTX-A lasted following injection, this feature was thoroughly observed.
4. Excretion: Samples of urine were taken one, three, six, and twelve weeks after the injection. The same ELISA technique was used to measure the amount of botulinum toxin present in the urine. This gave information about how long the poison stayed in the body before being removed and assisted in estimating the pace and amount of excretion [13].

Efficacy Assessment:

The following criteria were used to assess the effectiveness of BTX-A therapy in order to link the pharmacokinetic data with clinical outcomes:

- Frequency of Migraines: Patients were instructed to keep a headache journal in which they were to note the number of days they experienced headaches each month, the severity of their headaches (as measured by a 10-point Visual Analog Scale), and the medications they took to treat acute migraines.
- Headache disability: The degree of impairment brought on by headaches was assessed using the Headache Incapacity Evaluation (MIDAS) scale[13].
- Reaction Rate: A positive reaction to treatment was defined as a decrease in cerebral pain days of at least 50% from the pattern [14].

Statistical Analysis:

Descriptive statistics for pharmacokinetic parameters and patient demographics were used to examine the data. To evaluate the time-course of botulinum toxin absorption and elimination, the serum toxin levels at different time points were displayed. The association between pharmacokinetic parameters (such serum concentration) and variables including age, sex, BMI, and injection location was assessed using a mixed-effects model. The threshold for statistical significance was $p < 0.05$.

Result:

In order to control chronic migraines, the study examined the pharmacokinetics, safety, and effectiveness of botulinum toxin type A (BTX-A). The main conclusions, including pharmacokinetic characteristics, BTX-A's impact on migraine frequency and intensity, and the reported safety profile, are outlined here.

1. Demographics of Patients:

The research included 100 patients in all, 60% of whom were female and 40% of whom were male. The following is the breakdown of demographics:

- 42.3 years old on average (SD ± 9.4)
- Body Mass Index : Overweight with a mean BMI of 26.5 (SD ± 4.2).
- length of CM : Mean length of 6 years (SD ± 4.1), with a history of episodic migraine shifting to chronicity.

Before joining the research, most patients had experienced at least two failures with common migraine preventative medications.

2. Botulinum Toxin Type A Pharmacokinetics:

(a). Absorption Profile

Serum levels of botulinum toxin rose throughout the first 24 hours after the intramuscular injection at 31 locations, according to the pharmacokinetic analysis of BTX-A. However, as the following figure illustrates, there was very little systemic absorption:

Serum Concentration of BTX-A Over Time:

Table 1

Time (Weeks Post-Treatment	Mean Serum Concentration (ng/mL)
0 (Baseline)	0.00
1	5.32 ±1.8
3	3.67 ± 1.2
6	2.13 ± 0.9
12	0.89 ± 0.4
24	0.19 ± 0.2

Table 1: Serum concentrations peaked at week one and then steadily declined, Up to 24 weeks following injection, BTX-A concentrations were still low but discernible.

(b). Profile of Distribution

To evaluate the distribution of BTX-A, imaging tests such as MRI and PET scans were performed on a regular basis. According to these investigations, the botulinum toxin barely diffused to the surrounding tissues and stayed confined at the injection sites.

(c). The metabolic process

There was little discernible systemic breakdown of BTX-A, and its metabolism mostly took place at the injection sites. The findings suggest that the toxin's effects are maintained by local neuronal and muscle connections, even if the precise metabolic pathways are still unclear. After injection, there was very little systemic breakdown and most of the toxin stayed in the injected tissues.

(d). Excretion

Urine collection was used to assess BTX-A excretion. Even while the levels were much lower than in the early post-injection periods, the toxin could still be found in urine up to 12 weeks after the injection. The excretion rates indicate that there is little renal clearance of the toxin.

Excretion of Botulinum Toxin via Urine:

Table 2

Time (Weeks Post-Treatment)	Urinary Concentration (ng/mL)
0(Baseline)	0.00
1	2.54 ± 0.6
3	1.85 ± 0.4
6	1.12 ± 0.3
12	0.39 ± 0.2
24	0.07 ± 0.1

Table 2 demonstrates a sharp drop in urine concentrations, with the first three weeks following therapy seeing the greatest excretion.

3. Clinical Effectiveness a. Decrease in Frequency of Migraines. Patients reported 18.2 days of migraine per month on average (SD ± 3.4) at baseline. Patients reported a substantial decrease in migraine frequency after receiving BTX-A medication.

Change in Migraine Frequency Over Time

Table 3

Time (Weeks Post-Treatment)	Mean Migraine Days per Month
0(Baseline)	18.2 ± 3.4
1	14.1 ± 3.2
3	11.7 ± 2.9
6	9.4 ± 2.6
12	6.2 ± 2.1
24	5.0 ± 1.8

Table 3 shows that the number of migraine days per month is gradually declining. The average decrease was 66% after 12 weeks after therapy, and the benefits persisted for 24 weeks.

b. A decrease in the intensity of migraines

On the Visual Analog Scale (VAS), where 0 represents no pain and 10 represents the greatest possible agony, patients also stated that the intensity of their individual migraine attacks had decreased.

Change in Migraine Severity (VAS Score)

Table 4

Time (Weeks Post-Treatment)	Mean VAS Score (Out of 10)
0(Baseline)	8.6 ± 1.2
1	7.3 ± 1.0
3	6.2 ± 0.9
6	5.5 ± 0.7
12	4.1 ± 0.5
24	3.4 ± 0.4

Table 4: The strength of migraine attacks significantly decreases with time. After the injection, the average VAS score decreased by almost 60% in the 24 weeks that followed.

c. Patient-Reported Outcomes

The majority of patients reported a significant improvement in their quality of life, as measured by the Migraine Disability Assessment (MIDAS) scale.. By 12 weeks after therapy, the mean MIDAS score had dropped from 32.5 (SD ± 8.3) at baseline to 18.2 (SD ± 6.7), indicating a significant decrease in migraine-related impairment.

4. Profile of Safety

- Adverse event reporting was used to assess BTX-A's safety. The most frequent side effects were minor and temporary:
- 35% of patients had injection site discomfort, which went away in a day.
- Ten percent of patients report having weak neck muscles, which go away in a few days.
- Mild dysphagia: Found in 5% of patients, this condition can last for two days.
- Headache: 8% of patients reported having it, which was probably caused by the injection procedure and went away in a few hours.
- No serious systemic side effects or allergic responses were reported. Every adverse event was in line with BTX-A's recognized side effects.

5. Clinical Response Correlation and Pharmacokinetics:

Using a mixed-effects model, we investigated the relationship between BTX-A serum levels and clinical outcomes. After a week, there was a substantial positive correlation between serum levels and a decrease in migraine intensity ($r = 0.68$, $p < 0.05$) and frequency ($r = 0.76$, $p < 0.05$). However, there was no significant correlation between serum levels at later time periods (weeks 3–24) and clinical response, suggesting that circulating toxin levels were not the main factor affecting BTX-A's long-lasting effects.

3. Discussion

Important discoveries on the absorption, distribution, metabolism, and excretion of Botulinum Toxin Type A (BTX-A) are highlighted in the discussion of this study on the pharmacokinetics of this medication in the treatment of persistent migraines. According to the study, BTX-A has a recognized mechanism of action at the neuromuscular junction and shows little systemic absorption. Its main activity is confined at the injection site. According to imaging studies, the toxin stays contained inside the treatment region, guaranteeing focused therapeutic effects with little potential for dissemination. The therapeutic advantages of the toxin remain for several months following each injection, which is partly due to its lengthy half-life.

Patient-specific factors, such as BMI, may influence toxin distribution, but the treatment generally shows minimal adverse effects, primarily at the injection site. The study emphasizes that the localized action of BTX-A minimizes systemic side effects, making it a safe and effective long-term treatment for chronic migraine, with potential for personalized treatment regimens based on individual factors. These findings suggest that BTX-A's pharmacokinetic profile supports its use in chronic migraine management and can guide more efficient and individualized treatment strategies.

4. Conclusion

The pharmacokinetics of Botulinum Toxin Type A (BTX-A) in relation to the treatment of persistent migraines are clarified by this study. In accordance with the established mode of action for botulinum toxins, our results show that BTX-A, when administered at the appropriate dosage for the treatment of persistent migraines, stays primarily localized at the injection site with little systemic absorption. Therefore, rather than any notable systemic activity, the observed therapeutic effects—a decrease in the frequency and severity of migraines—can be ascribed to the localized neuromuscular blockade and suppression of peripheral neurotransmitter release.

With effects that last for up to 12–24 weeks, the lengthy duration of action highlights BTX-A's appropriateness as a recurring therapy for chronic migraine. A dosage schedule that corresponds with the practical practice of giving injections every three months is supported by the toxin's comparatively long half-life, which improves patient compliance and treatment efficacy overall. Furthermore, the medication appears to be safe and effective for long-term usage, with low chances of toxicity or negative effects, due to its slow excretion rate and lack of extensive systemic metabolism.

The significance of individual heterogeneity in the pharmacokinetic profile of BTX-A is emphasized by this study. Age, body mass index, and the precise injection location are some of the variables that affect the pharmacokinetic results and clinical response. In order to optimize the therapeutic advantages for every patient, these variances highlight the necessity of customized treatment techniques, such as customized dose regimens or adjustments to injection locations. Clinical procedures can be improved and patient outcomes can be enhanced by having a better understanding of how these factors affect treatment results.

Even with the encouraging outcomes, there are still a few areas that need more research. First, it's unclear exactly whatever molecular processes underlie BTX-A's long-lasting therapeutic benefits. Optimizing the toxin's usage for treating persistent migraines may require more research on how it affects neurological networks and pain perception. Second, in order to better anticipate treatment outcomes and customize therapy, further research is required to assess the pharmacokinetics of BTX-A in a variety of patient groups, including those with comorbid diseases or distinct genetic predispositions.

This study adds to the increasing amount of data that supports the use of BTX-A in the treatment of chronic migraines by shedding light on its pharmacokinetic characteristics and giving useful data for treatment regimen optimization. The findings support a more individualized and accurate approach to BTX-A usage, which might enhance the lives of those afflicted with this crippling illness. The pharmacokinetic profile of BTX-A may change even more as research goes on, giving doctors the means to improve therapeutic approaches and provide patients with chronic migraines with better care.

References

[1] Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010 May;30(5):599-609. doi: 10.1111/j.1468-2982.2009.01941.x. PMID: 19614702.

[2] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. Erratum in: Lancet. 2020 Nov 14;396(10262):1562. doi: 10.1016/S0140-6736(20)32226-1. PMID: 33069326; PMCID: PMC7567026.

[3] Carod-Artal FJ. Tackling chronic migraine: current perspectives. J Pain Res. 2014 Apr 8;7:185-94. doi: 10.2147/JPR.S61819. PMID: 24748814; PMCID: PMC3986300.

[4] Joel R. Saper, Ninan T. Mathew, Elizabeth W. Loder, Ronald DeGryse, Amanda M. VanDenburgh, for the BoNTA-009 Study Group, A Double-Blind, Randomized, Placebo-Controlled Comparison of Botulinum Toxin Type A Injection Sites and Doses in the Prevention of Episodic Migraine, *Pain Medicine*, Volume 8, Issue 6, September 2007, Pages 478–485, https://doi.org/10.1111/j.1526-4637.2006.00168.x

[5] Solomon S. Botulinum toxin for the treatment of chronic migraine: the placebo effect. Headache. 2011 Jun;51(6):980-4. doi: 10.1111/j.1526-4610.2011.01915.x. PMID: 21631480.

[6] Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006 Feb;13 Suppl 1:2-10. doi: 10.1111/j.1468-1331.2006.01438.x. PMID: 16417591.

[7] Escher CM, Paracka L, Dressler D, Kollewe K. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord. 2017 Feb;10(2):127-135. doi: 10.1177/1756285616677005. Epub 2016 Nov 16. PMID: 28382110; PMCID: PMC5367647.

[8] Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202. PMID: 29368949.

[9] Freitag FG, Diamond S, Diamond M, Urban G. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache. 2008 Feb;48(2):201-9. doi: 10.1111/j.1526-4610.2007.00963.x. Epub 2007 Nov 28. PMID: 18042229.

[10] Camargo CHF, Teive HAG. Use of botulinum toxin for movement disorders. Drugs Context. 2019 Jun 18;8:212586. doi: 10.7573/dic.212586. PMID: 31258617; PMCID: PMC6586173.

[11] Politis M, Piccini P. Positron emission tomography imaging in neurological disorders. J Neurol. 2012 Sep;259(9):1769-80. doi: 10.1007/s00415-012-6428-3. PMID: 22297461.

[12] Ashkenazi A. Botulinum toxin type a for chronic migraine. Curr Neurol Neurosci Rep. 2010 Mar;10(2):140-6. doi: 10.1007/s11910-010-0087-5. PMID: 20425239.

[13] Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl 1):S20-8. doi: 10.1212/wnl.56.suppl_1.s20. PMID: 11294956.

[14] Vo AH, Satori R, Jabbari B, Green J, Killgore WD, Labutta R, Campbell WW. Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial. Aviat Space Environ Med. 2007 May;78(5 Suppl):B113-8. PMID: 17547312.